Myelofibrosis (MF) is one of a group of heterogeneous hematopoietic disorders that constitute myeloproliferative neoplasms (MPNs). The severity of these disorders can range from mild to aggressive, and the diseases are associated with shortened survival and greatly compromised quality of life. Cytopenias in MF are common, and often problematic, and are the most common reason for treatment interruption and/or dose reduction. Our expert panel will guide us in an interactive discussion on the unmet medical need for patients with cytopenic MF, the current treatment approaches, and emerging therapies that can be used in cytopenic patients.
The goal of this activity is to improve the knowledge of hematologists/oncologists about cytopenic myelofibrosis and the emerging treatment approaches.
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Criteria for diagnosis of cytopenic MF [ITEM]Efficacy of emerging approaches to treating cytopenic MF [ITEM]Safety of emerging approaches to treating cytopenic MF[/LIST] Demonstrate greater confidence in their ability to [LIST][ITEM]Identify patients with cytopenic MF[/LIST]
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[BOLD]For Physicians[/BOLD] Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.